Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs

Atara Biotherapeutics, Inc. announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel or Ebvallo).

Building on the earlier partnership announced in October 2021 to commercialize tab-cel in Europe, this transaction provides Pierre Fabre Laboratories with the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets.

With the closing of the transaction, Atara will receive approximately $ 27 million in cash upfront and initial inventory purchase. Under the agreement, Atara has the potential to receive up to a total of $ 640 million and significant double-digit tiered royalties on net sales, including up to $ 100 million in potential regulatory milestones through BLA approval. In addition, Pierre Fabre Laboratories will reimburse Atara for expected tab-cel global development costs through the Biologics License Application (BLA) transfer, and purchase future tab-cel inventory through the manufacturing transfer date.

Ebvallo is EU approved for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).